Progress, Potential, and Possibilities Podcast / Show

Ira Pastor

Interviews and Discussions With Fascinating People Who are Creating A Better Tomorrow For All Of Us - Host - Ira S. Pastor

  1. 19h ago

    Beyond Immunosuppression: The Rise of T-Cell Engagers for Autoimmune Disease | Dr. Jeffrey Jones, MD, MPH - Chief Medical Officer, Cullinan Therapeutics

    Send us Fan Mail For decades we've treated autoimmune diseases by suppressing the immune system - but what if we've been approaching the problem all wrong? What if, instead of lifelong immunosuppression, we could selectively eliminate the immune cells causing disease and allow the immune system to rebuild itself? Today we're exploring one of the hottest areas in biotechnology: T-cell engagers and the possibility of an "immune reset." Dr. Jeffrey Jones, MD, MPH is Chief Medical Officer of Cullinan Therapeutics ( https://cullinantherapeutics.com/ ) and one of the leaders helping bring the power of T-cell engager therapies beyond cancer and into autoimmune disease. With more than two decades of experience spanning academia and industry, Dr. Jones has been at the forefront of clinical development in hematology, oncology, and immunology. Prior to joining Cullinan, Dr. Jones served as Vice President of Global Drug Development at Bristol Myers Squibb, leading programs in lymphoma and myeloid diseases and helping guide the lifecycle strategy for Reblozyl®. Earlier, he held leadership positions at Celgene, where he developed clinical strategies across lymphoma and chronic lymphocytic leukemia portfolios. Before entering industry, Dr. Jones spent more than a decade at The Ohio State University, where he led the Chronic Lymphocytic Leukemia clinical research program and served as Associate Professor of Internal Medicine. Today, he is helping pioneer a new generation of T-cell engagers designed not to continuously suppress the immune system, but potentially to reset it - opening the possibility of durable, treatment-free remission for diseases such as rheumatoid arthritis, lupus, lupus nephritis, and autoimmune cytopenias. Dr. Jones earned his MD from the University of Michigan Medical School, an MPH from the University of Texas School of Public Health, and an MBA from The Ohio State University Fisher College of Business. #AutoimmuneDisease #Lupus #RheumatoidArthritis #Immunology #TCellEngagers #Biotechnology #DrugDevelopment #PrecisionMedicine #ImmuneSystem #ImmuneReset #ClinicalTrials #Biotech #HealthcareInnovation #FutureOfMedicine #ProgressPotentialPossibilities Support the show

    55 min
  2. 19h ago

    Inside Israel's Health Innovation Revolution | Dr. Michal Tzuchman-Katz, MD - Chief Innovation & Research Officer, Maccabi Healthcare Services

    Send us Fan Mail Can artificial intelligence really think like a physician - or is it simply predicting words? This week we're joined by Dr. Michal Tzuchman-Katz, MD, physician, AI entrepreneur, pediatrician, and Chief Innovation & Research Officer at Maccabi Healthcare, one of the world's most advanced healthcare organizations. We explore why the future of medicine isn't just better AI - it's building healthcare systems that learn from every patient. Dr. Michal Tzuchman-Katz, MD is a physician, technologist, entrepreneur, and healthcare innovation leader who currently serves as Chief Innovation & Research Officer at Maccabi Healthcare Services ( https://www.maccabi4u.co.il/ ), one of Israel’s largest and most advanced healthcare organizations. What makes Dr. Tzuchman-Katz’s story extraordinary is that she has worked across nearly every layer of modern health technology. She began her career as a software engineer, earned her medical degree with honors, trained as a pediatrician, studied genomics and biomedical informatics, and went on to co-found and lead Kahun, an AI-powered clinical reasoning company that developed a knowledge-graph engine containing more than 30 million evidence-based medical insights. At Kahun, Dr. Tzuchman-Katz became a pioneer in explainable AI for physicians, focusing on making AI-generated recommendations transparent, traceable to medical evidence, and aligned with the way clinicians actually think.  Today, at Maccabi, Dr. Tzuchman-Katz oversees innovation and research initiatives that leverage one of the world’s richest longitudinal healthcare datasets and biobanks to develop and scale technologies that can improve patient outcomes at population level. Remarkably, while leading innovation for a major healthcare system, Dr. Tzuchman-Katz continues to practice as a pediatrician, giving her a uniquely grounded perspective on the promises and limitations of AI in real clinical care. #HealthcareInnovation #ArtificialIntelligence #MedicalAI #PrecisionMedicine #HealthTech #DigitalHealth #ClinicalAI #Medicine #Healthcare #Biotech #Genomics #Innovation #FutureOfMedicine #HealthcareData #MachineLearning #MedicalResearch #Pediatrics #PreventiveMedicine #PersonalizedMedicine #PPP Support the show

    47 min
  3. 4d ago

    Beyond Ignition: The Engineering Challenge That Will Decide Fusion's Future | Dr. Will Regan, Ph.D. - Founder and Chief Scientist, Pacific Fusion

    Send us Fan Mail For decades, fusion researchers were chasing a single goal: ignition. But what if ignition isn't the finish line? What if it's only the starting gun? Today we're joined by Dr. Will Regan, Founder and Chief Scientist of Pacific Fusion, a company betting that the future of fusion won't be won by building bigger machines - but by solving one of engineering's toughest manufacturing challenges. Dr. Will Regan, Ph.D. is the Founder and Chief Scientist of Pacific Fusion ( https://www.pacificfusion.com/ ), where he is helping lead one of the most ambitious efforts in advanced inertial fusion energy: developing a practical, scalable pathway to commercial fusion power using pulsed power systems and high-yield target physics. Before founding Pacific Fusion, Will served as a Project Lead and Rapid Evaluator at X, the moonshot factory, where he helped originate and develop breakthrough concepts in agricultural and systems innovation, including early foundational work behind the Mineral initiative focused on sustainable food production at planetary scale. Earlier in his career, he was an ARPA-E Fellow at Advanced Research Projects Agency–Energy, where he worked at the intersection of high-risk, high-reward energy technologies and national-scale innovation programs—an experience that helped shape his approach to large-scale energy system design and technology acceleration. Will earned his PhD in Physics from University of California, Berkeley, following his undergraduate degree in Physics from Cornell University. Across academia, government, and moonshot industry environments, he has consistently focused on translating frontier physics into real-world systems—now centered on one of the most consequential engineering challenges of the century: fusion energy. At Pacific Fusion, he is working to turn high-gain fusion concepts into repeatable, engineered systems that could fundamentally reshape global energy infrastructure. #FusionEnergy #NuclearFusion #PacificFusion #WillRegan #CleanEnergy #FutureOfEnergy #FusionPower #InertialConfinementFusion #ICF #MagLIF #SandiaLabs #LawrenceLivermore #NIF #AdvancedEnergy #EnergyInnovation #Physics #Engineering #ClimateTech #MoonshotFactory #ARPAE #SciencePodcast #TechnologyPodcast #ProgressPotentialPossibilities #STEM #DeepTech Support the show

    37 min
  4. 4d ago

    Growing Plants in Space: The Science Behind Future Moon and Mars Colonies | Mark Ciotola - CEO and Co-Founder, Sustain Space

    Send us Fan Mail Everyone talks about getting humans to Mars. But almost nobody talks about the harder question - how do you keep them alive once they get there? My guest today says the answer isn't bigger rockets - it's plants. Mark Ciotola is CEO and Co-Founder of Sustain Space ( https://www.sustainspace.com/ ), a company focused on developing regenerative life-support technologies for future space missions while translating those innovations to improve agriculture and sustainability on Earth. Through Sustain Space's Orbital Genomics initiative, he is helping advance research into growing plants in space environments - an essential capability for long-duration missions to the Moon, Mars, and beyond. Mark's career spans entrepreneurship, academia, industry, and government, including work with NASA, Genentech, Applied Biosystems, Intuit, Carnegie Mellon University, Monash University, San Francisco State University, and Singularity University, where he served as Entrepreneur-in-Residence and faculty member in Space and Physical Sciences. A physicist, entrepreneur, educator, and sustainability advocate, Mark is particularly interested in regenerative ecosystems, closed-loop life-support systems, space agriculture, and the broader question of how humanity can build a sustainable future both on Earth and beyond it. Important Episode Link - HudsonAlpha Institute for Biotechnology - https://www.hudsonalpha.org/ #MarkCiotola #SustainSpace #SpaceAgriculture #SpaceFarming #MarsColonization #MoonBase #NASA #SpaceBiology #Astrobiology #PlantScience #OrbitalGenomics #ControlledEnvironmentAgriculture #VerticalFarming #Hydroponics #SyntheticBiology #FutureOfFood #SpaceTechnology #SpaceExploration #LifeSupportSystems #ClosedLoopSystems #MarsMission #MoonMission #Humanity #Innovation #SciencePodcast #STEM #FutureOfHumanity #ProgressPotentialPossibilities Support the show

    49 min
  5. 6d ago

    Delirium, Dementia & Protecting the Aging Brain | Dr. Tammy Hshieh, MD, MPH - Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife

    Send us Fan Mail We often assume confusion after surgery is temporary. But what if those few days of delirium are actually a major turning point in the aging brain? New research from Harvard and Hebrew SeniorLife suggests postoperative delirium may be the strongest predictor of long-term cognitive decline - and what we're learning could fundamentally change how we think about dementia and healthy aging. Each year, millions of older adults undergo surgery successfully, only to experience episodes of confusion, disorientation, memory impairment, or altered awareness in the days that follow. For decades, many clinicians viewed postoperative delirium as a temporary complication that resolved once patients left the hospital. But emerging research suggests a much more profound story. Our guest today is Dr. Tammy Hshieh, MD, MPH, is physician-scientist, geriatrician, and internationally recognized expert on delirium, cognitive impairment, and healthy aging.  Dr. Hshieh serves as Assistant Scientist at the Hinda and Arthur Marcus Institute for Aging Research at Hebrew SeniorLife ( https://www.marcusinstituteforaging.org/who-we-are/profiles/tammy-hshieh-md-mph ), Assistant Professor of Medicine at Harvard Medical School ( https://connects.catalyst.harvard.edu/Profiles/display/Person/33333 ), and Associate Physician at Brigham and Women's Hospital ( https://physiciandirectory.brighamandwomens.org/Details/12170 ). After earning her undergraduate degree in Biochemistry from Harvard University and her MD from Brown University's Alpert Medical School, Dr. Hshieh completed residency training in Internal Medicine at Beth Israel Deaconess Medical Center, a fellowship in Geriatric Medicine through Harvard Medical School, and earned a Master of Public Health from the Harvard T.H. Chan School of Public Health. Dr. Hshieh's research focuses on understanding, preventing, and treating delirium and cognitive decline in older adults - conditions that carry enormous consequences for independence, quality of life, and healthcare systems worldwide. In groundbreaking work recently published in JAMA Internal Medicine, Dr. Hshieh and colleagues demonstrated that postoperative delirium remains the strongest predictor of long-term cognitive decline, even after accounting for rehospitalizations and other markers of illness and frailty. Their findings suggest that delirium may represent far more than a transient hospital complication - it may be a critical turning point in the trajectory of brain aging itself. Clinically, Dr. Hshieh co-manages older surgical patients at Brigham and Women's Hospital in one of the nation's most innovative geriatric-surgical care programs and leads the Older Adult Hematologic Malignancy Clinic at Dana-Farber Cancer Institute ( https://www.dana-farber.org/find-a-doctor/tammy-t-hshieh ), where she works to improve outcomes for older adults facing cancer treatment. Today we'll discuss delirium, dementia, cognitive resilience, surgical risk, brain aging, and what patients, families, and healthcare systems can do to better protect the aging brain. #Delirium #Dementia #BrainHealth #HealthyAging #CognitiveDecline #Alzheimers #HarvardMedicine #Geriatrics #Longevity #Surgery #PostoperativeDelirium #AgingResearch #Neuroscience #Healthcare #Medicine #BrainAging #CognitiveHealth #Prevention #Podcast #ProgressPotentialPossibilities Support the show

    39 min
  6. 6d ago

    The Inventor Who Revolutionized Heart Monitoring | Dr. David Albert, MD - Founder, AliveCor

    Send us Fan Mail What if a device small enough to fit in your pocket could detect a potentially fatal heart rhythm before symptoms even appear? My guest today helped make that possible. Dr. David Albert, MD - Founder of AliveCor, pioneered smartphone ECG technology and transformed how millions of people monitor their hearts. Dr. David Albert, MD is a physician, inventor, and serial entrepreneur whose career has helped define the modern era of digital cardiology and personal health technology.  A graduate of Harvard College and Duke University School of Medicine, Dr. Albert has spent more than four decades translating breakthrough ideas into life-saving products. He founded Corazonix in the 1980s, Data Critical in the 1990s - which later became part of GE Healthcare - and ultimately served as Chief Scientist and Chief Clinical Scientist for GE Cardiology before returning to entrepreneurship. In 2010, Dr. Albert founded AliveCor ( https://alivecor.com/ ), pioneering the smartphone-based ECG and helping launch one of the earliest and most clinically validated digital health platforms. AliveCor’s KardiaMobile technology transformed cardiac monitoring by placing medical-grade electrocardiograms in the hands of millions of consumers and patients worldwide.  Beyond AliveCor, Dr. Albert founded InnovAlarm and Lifetone Technology, developing innovations that improve home safety and emergency alerting.  An inventor with more than 80 U.S. patents and over 100 scientific publications, Dr. Albert has devoted his career to democratizing healthcare technology and empowering people to better understand - and protect - their own health. #DavidAlbert #AliveCor #KardiaMobile #DigitalHealth #Cardiology #HeartHealth #ECG #AtrialFibrillation #WearableTech #HealthcareInnovation #MedTech #RemoteMonitoring #AIinHealthcare #PrecisionMedicine #PreventiveMedicine #Entrepreneurship #HealthcareTechnology #GEHealthcare #MedicalDevices #FutureOfMedicine #DigitalBiomarkers #HealthTech #Inventor #StartupFounder #Cardiologist #PatientEmpowerment #HeartDisease #MedicalInnovation #ProgressPotentialPossibilities Support the show

    57 min
  7. Jun 29

    Systemic Oncolytic Virotherapy Explained | Dr. Eric Poma, Ph.D. - CEO - Calidi Biotherapeutics

    Send us Fan Mail For decades, scientists have searched for better cancer drugs. But what if the biggest challenge isn't discovering the drug - it's getting it to the tumor? My guest today is developing programmable viruses designed to travel throughout the body, selectively amplify inside metastatic lesions, and transform tumors into factories for their own destruction. Dr. Eric Poma, Ph.D. is Chief Executive Officer of Calidi Biotherapeutics ( https://www.calidibio.com/ ), a biotechnology company developing targeted genetic medicines designed to deliver therapeutic payloads directly to tumors throughout the body. Dr. Poma brings more than three decades of experience across biotechnology, oncology drug development, business development, and capital markets. Prior to joining Calidi in 2025, he served as CEO of Molecular Templates, where he helped raise more than $250 million in equity financing and secured strategic partnerships with companies including Takeda, Vertex, and Bristol Myers Squibb. Earlier in his career, Dr. Poma held leadership roles at ImClone Systems during the rise of targeted cancer therapies, served as Vice President of Business Development at Innovive Pharmaceuticals, and worked as a healthcare and biotechnology analyst. He holds a Ph.D. in Microbiology and Immunology from the University of North Carolina at Chapel Hill and an MBA from NYU's Stern School of Business. Today we will discuss one of the most difficult challenges in oncology - how to successfully deliver powerful therapies to metastatic tumors throughout the body - and how Calidi's RedTail platform aims to use engineered oncolytic viruses as targeted delivery vehicles capable of reaching cancer cells, modifying the tumor microenvironment, and potentially enabling a new generation of genetic medicines. #CancerResearch #Oncology #Immunotherapy #GeneTherapy #Biotechnology #CancerTreatment #PrecisionMedicine #OncolyticVirus #CancerScience #BiotechInnovation #MetastaticCancer #IL15 #VacciniaVirus #GeneticMedicine #SyntheticBiology #TumorMicroenvironment #FutureOfMedicine #DrugDelivery #Biopharma #EricPoma #CalidiBiotherapeutics #CancerBreakthrough #MedicalInnovation #LifeSciences #ProgressPotentialPossibilities Support the show

    36 min
  8. Jun 26

    The Blood Test That Could Change Cancer Treatment Forever | Eric Matthews - General Manager, Biopharma, Natera

    Send us Fan Mail For decades, oncologists have had to wait until cancer became visible on a scan before knowing whether it had returned. But what if doctors could detect microscopic traces of cancer months earlier with a simple blood draw - and use that information to decide who actually needs treatment? Today we're exploring a breakthrough that may fundamentally change the way cancer is monitored and treated. Eric Matthews is General Manager of Biopharma at Natera ( https://www.natera.com/ ), a leader in personalized molecular diagnostics and the company behind Signatera, the first FDA-approved molecular residual disease companion diagnostic. Over the past 25 years, Eric has helped bring nine medicines to market across nineteen indication launches, building a career at the forefront of oncology, precision medicine, and biopharmaceutical innovation. Before joining Natera, Eric served as Chief Business Officer at Caris Life Sciences, where he focused on diagnostic, data, and drug discovery partnerships. Prior to that, he was Chief Commercial Officer at Arcus Biosciences, helping forge major strategic collaborations including Arcus' landmark partnership with Gilead Sciences. Eric's previous leadership roles include Vice President of Global Marketing for Immuno-Oncology at AstraZeneca and commercial leadership positions at Genentech and Roche, where he worked on some of the most influential cancer therapies of the modern era, including Avastin and Tecentriq. Eric holds an MBA in Health Sector Management, a Master's in Health Policy and Economics, and dual bachelor's degrees in Molecular Biology and Economics from Duke University. Today we discuss the future of molecular residual disease testing, how personalized blood-based diagnostics are changing cancer care, the recent FDA approval of Signatera as the first MRD companion diagnostic, and what the next decade may hold for truly individualized oncology. #CancerResearch #CancerDetection #PrecisionMedicine #Oncology #LiquidBiopsy #Signatera #Natera #CancerCare #Biotech #HealthcareInnovation #Immunotherapy #Tecentriq #BladderCancer #MolecularBiology #PersonalizedMedicine #CancerTreatment #MedicalInnovation #FutureOfMedicine #Biotechnology #ProgressPotentialPossibilities Support the show

    25 min

Ratings & Reviews

5
out of 5
6 Ratings

About

Interviews and Discussions With Fascinating People Who are Creating A Better Tomorrow For All Of Us - Host - Ira S. Pastor

You Might Also Like